Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications

  title={Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications},
  author={Gabriella Marucci and Diego Dal Ben and Michela Buccioni and Aleix Mart{\'i} Navia and Andrea Spinaci and Rosaria Volpini and Catia Lambertucci},
  journal={Expert Opinion on Therapeutic Patents},
  pages={943 - 963}
ABSTRACT Introduction: Purinergic P2X3-P2X2/3 receptors are placed in nociceptive neurons’ strategic location and show unique desensitization properties; hence, they represent an attractive target for many pain-related diseases. Therefore, a broad interest from academic and pharmaceutical scientists has focused on the search for P2X3 and P2X2/3 receptor ligands and has led to the discovery of numerous new selective antagonists. Some of them have been studied in clinical trials for the treatment… 

P2X receptor antagonists and their potential as therapeutics: a patent review (2010–2021)

This review provides a summary of the patent literature describing the discovery and clinical uses of P2X receptor antagonists published between 2010 and September 2021 and the reader will gain information on structural claims, representative structures, and biological data of recently reported P2x antagonists.

Update of P2X receptor properties and their pharmacology: IUPHAR Review 30

Crystallization allowed the identification of the 3D structure and gating cycle of P2X receptors, including the agonist‐binding pocket, and a range of subtype‐selective antagonists, as well as positive and negative allosteric modulators.

P2X3 Receptor Ligands: Structural Features and Potential Therapeutic Applications

P2X3Rs undergo rapid inactivation/desensitization during exposure to ATP or to the selective agonist α,β-methyleneATP (α, β-meATP, 2, Figure 1), which is accelerated by increasing the agonist dose, while P2X2/3Rs shows either mixed (twocomponent) or slow-type desensitizing (Giniatullin and Nistri, 2013).

The P2Y/P2X divide: how it began.

Association between P2X3 receptors and neuropathic pain: As a potential therapeutic target for therapy.

Novel Analgesics with Peripheral Targets

  • Cosmin I. CiotuM. Fischer
  • Biology
    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
  • 2020
An overview of publication activity is presented, considering a IuPhar/BPS-curated list of targets with restriction to pain-related publications, which was also used to identify topics.

Recommended tool compounds and drugs for blocking P2X and P2Y receptors

This review article presents a collection of tool compounds that selectively block and are recommended for studying P2Y and P2X receptor subtypes, investigating their roles in physiology and

Emerging drugs for the treatment of bladder storage dysfunction

  • K. Andersson
  • Medicine, Biology
    Expert opinion on emerging drugs
  • 2022
Focus is given to P2X3 receptor antagonists, small molecule blockers of TRP channels, the roles of cannabis on incontinence in patients with multiple sclerosis, and of drugs acting directly on CB1 and CB2 receptor or indirectly via endocannabinoids by inhibition of fatty acid aminohydrolase.



Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists.

P2X3 and P2X2/3 receptor antagonists.

This review provides a concise summary of the molecular properties of the ligand-gated P2X receptors, in particular those containing the X3 subunit, as well as an overview comprising the most

Pharmacology of P2X channels

The recent advancement of drug candidates targeting P2x channels into human trials, confirms the medicinal exploitability of this novel target family and provides hope that safe and effective medicines for the treatment of disorders involving P2X channels may be identified in the near future.

P2X Receptors as Drug Targets

The determination of the atomic structure of P2X receptors in closed and open (ATP-bound) states by X-ray crystallography is now allowing new approaches by molecular modeling, supported by a large body of previous work using mutagenesis and functional expression, and now being supplemented by molecular dynamic simulations and in silico ligand docking.

Discovery of Potent Antiallodynic Agents for Neuropathic Pain Targeting P2X3 Receptors.

Intravenous injection of compound 28 resulted in potent antiallodynic effects, with ED50 values of 2.62 and 2.93 mg/kg in spinal nerve ligation and chemotherapy-induced peripheral neuropathy rats, respectively, indicating that new drug development targeting the P2X3 receptor could be promising for neuropathic pain, a disease with high unmet medical needs.

Medicinal chemistry of P2X receptors: agonists and orthosteric antagonists.

A significant improvement has been gained from the interest of pharmaceutical companies that in the last years discovered, through the use of high-throughput screening, potent and selective antagonists endowed with novel structures, some of which are currently in clinical trials for several therapeutic applications.

Purinergic P2X Receptors: Physiological and Pathological Roles and Potential as Therapeutic Targets.

Since the publication of the early studies ('50s-'60s) suggesting a role played by purine nucleotides in the extracellular environment, an increased interest was devoted to the investigation and

A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat

The present data indicate that a potent and selective antagonist of P 2X3 and P2X2/3 receptors effectively reduces both nerve injury and chronic inflammatory nociception, but P2x3 andP2X 2/3 receptor activation may not be a major mediator of acute, acute inflammatory, or visceral pain.

Investigation on 2',3'-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists.

The design and synthesis of novel TNP-ATP analogues bearing alkyl groups in the 2',3'-position are reported and confirmed the P2X3 antagonist potency for some derivatives.